A Phase 3 interventional study of Taurine granule and Placebo in Prehypertension, sponsored by Zhiming Zhu. Completed at 1 site in China. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-24.
Sponsored by Zhiming Zhu · Phase 3, Interventional, and Prevention
Prehypertension are associated with an increased risk of atherosclerosis and coronary artery disease, and often complicated with the metabolic disorder of glucose and lipid. The comprehensive prevention of hypertension is still an important and complex clinical issue. Taurine is one of the ingredients of Chinese medicine bezoar ,as an endogenous amino acids is central inhibitory neurotransmitter, can regulate the excitability of nerve tissue, regulate body temperature, therefore, antipyretic, sedative, analgesic, anti-inflammatory,the role of anti-rheumatic, anti-convulsant. In addition, Taurine inhibits platelet aggregation in the circulatory system, lower blood lipids, to maintain the body's normal blood pressure and prevent atherosclerosis; protective effect on myocardial cells, can be anti-arrhythmic; special efficacy to lower blood cholesterol, to treat heart failure. The effect of oral Taurine on blood pressure is not consistent, however, many animal study has shown that oral administration of Taurine, could reduce 24-hour mean arterial systolic and diastolic blood pressure in spontaneous hypertensive rats. Furthermore, Taurine interfere with calcium and low affinity binding of the calcium binding sites, decrease the voltage-dependent Ca2+channel in vascular smooth muscle relaxation, vasodilation, lower blood pressure.In a prospective, double-blind, randomized, and parallel-group study, we will evaluate the effects of Taurine granule on blood pressure and metabolic parameters in prehypertensive and mild hypertensive patients. This study will help develop future comprehensive prevention and treatment strategies for hypertension.
151 studies on the registry are indexed under Prehypertension; 22 are open to participants now.
This study's enrollment of 120 is above the median of 64 across 133 interventional studies indexed under Prehypertension.
Browse Prehypertension studies →Zhiming Zhu is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Interventions Drug: Taurine granule Arms: Group 1
Drug: Taurine granule
Interventions Drug: Placebo Arms: Group 2
Drug: Placebo
1 package(1.6g taurine granule) once a day after meals, 12 weeks
Also known as: Taurine granule, H20003861.
Placebo: 1 package once a day after meals, 12 weeks
Also known as: Placebo packaged similar to Taurine granule
The decrease in blood pressure after an 12-week oral Taurine granule administration.
Evaluate the effects of Taurine granule on blood pressure and metabolic parameters in prehypertensive patients after an 12-week oral administration.
Time frame: 12 weeks
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhiming Zhu